William R. Arnold, Lauren N. Carnevale, Zili Xie, Javier L. Baylon, Emad
Tajkhorshid, Hongzhen Hu, and Aditi Das.
Anti-inflammatory dopamine- and serotonin-based endocannabinoid
epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.
Nature Communications, 12, 2021.
ARNO2021-ET
The endocannabinoid (eCB) system is a promising target to mitigate
pain as the eCBs are endogenous
ligands of the pain-mediating receptors—cannabinoid receptors 1 and 2
(CB1 and CB2) and TRPV1. Here
we report on a novel class of lipids formed by the epoxidation of N-
arachidonoyl-dopamine (NADA) and
N-arachidonoyl serotonin (NA5HT) by cytochrome P450 (CYP)
epoxygenases. These epoxides (epoNADA and
epoNA5HT) are dual-functional rheostat modulators (varying strength of
agonism or antagonism) of the
eCB-TRPV1 axis. In fact, epoNADA is a 6-fold stronger agonist of TRPV1
than NADA while epoNA5HT is a
30-fold stronger antagonist of TRPV1 than NA5HT and displays a
significantly stronger inhibition on
TRPV1-mediated responses in primary afferent neurons. Moreover,
epoNA5HT is a full CB1 agonist. The
epoxides reduce the pro-inflammatory biomarkers IL-6, IL-1,
TNF- and nitrous oxide
(NO) and raise anti-inflammatory IL-10 in activated microglial cells.
The epoxides are spontaneously
generated by activated microglia cells and their formation is
potentiated in the presence of another
eCB, anandamide (AEA). We provide evidence for the direct biochemical
mechanism of this potentiation
using human CYP2J2, a CYP epoxygenase in the human brain, using
detailed kinetics studies and
molecular dynamics simulations. Taken all together, inflammation leads
to an increase in the
metabolism of NADA, NA5HT and other eCBs by CYP epoxygenases to form
the corresponding epoxides. The
epoxide metabolites are bioactive lipids that are more potent, multi-
faceted endogenous molecules,
capable of influencing the activity of CB1, CB2 and TRPV1 receptors.
The identification of these
molecules will serve as templates for the synthesis of new multi-
target therapeutics for the
treatment of inflammatory pain.